ArticleDiagnostic and prognostic research2020

Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?

Gijs F N Berkelmans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.